Educational Course - Advancing Knowledge on ECP Technology

The Goal

To provide discussion opportunity on patient treatment with ECP across CTCL, GvHD, LuTx and HTx and department set-up.

Agenda

Download Agenda PDF

Day 1 - 19 November 2026

Arrival of participants

19.00 – 19.30
Meeting in the lobby

19.30
Dinner

Day 2 - 20 November 2026

09:00 – 09:15
Welcome and introduction - Therakos Healthcare Stakeholder Engagement Department

09:15 – 09:45
ECP usage according to the Medical Device Regulation (MDR) and approved indications in CTCL, GvHD, LuTx, HTx:The Birmingham experience - Prof Julia Scarisbrick

09.45 – 10.15
Patient-centered therapy using Therakos ECP technology – A holistic view of the GvHD patient journey - Dr Francesca Kinsella

10.15 – 10.45
ECP treatment pathway – a patient perspective - Patient TBC

10.45– 11.00
Interactive discussion - All

11.00 – 11.15
Coffee Break

11.15 – 11.45
Department and ECP set-up - Joanne Bird

11.45– 12.30
Visit to treatment area - All

12.30 – 13.30
Lunch

13.30 – 14.00
A nurse’s (operator’s) perspective on the Therakos ECP treatment - Cara Cunningham

14.00 – 14.30
Vascular access in ECP treatment - Joanne Bird

14.30 – 15.00
Managing patients – A cross-departmental approach - Laura Hazlett

15.00 – 15.15
Interactive discussion - All

15.15 – 15.30
Final remarks and close - Faculty

ECP: Extracorporeal photopheresis, GvHD: Graft versus Host Disease, LuTX:Lung Transplant CTCL: Cutaneous T-Cell Lymphoma, HTx:Heart Transplant

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session.

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is intended for healthcare professionals based in Europe and the Middle East.

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

Explore related courses

Nov 23 - 24, 2026

Tailoring ECP Treatment for Specific Patients’ Needs

Vall d'Hebron Barcelona University Hospital, Banc de Sang i Teixits, Barcelona, Spain

Find out more

Nov 26 - 27, 2026

THERAKOS™ CELLEX™ Photopheresis System - Advancing Knowledge on ECP Technology

The Tirol Kliniken, Innsbruck, Austria

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)
Treatment of immune related adverse events (irAE’s) associated with Immune checkpoint inhibitor (ICI) therapy in patients with inadequate response to corticosteroids

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.